Aaron D. Showalter

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

Francis S. Willard, Jonathan D. Douros, M Gabe et al. · JCI Insight · 2020 · 439 citations · Full text

Pharmacotherapy, Experimental Pharmacology, Insulin Signaling +20

Hepatic and glucagon-like peptide-1–mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors

Kyle W. Sloop, Julia X.C. Cao, Angela M. Siesky et al. · Journal of Clinical Investigation · 2004 · 210 citations · Full text

Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist

Takahiro Kawai, Bingfa Sun, Hitoshi Yoshino et al. · Proceedings of the National Academy of Sciences · 2020 · 172 citations · Full text

Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides

Merrill D. Benson, Barbara Kluve‐Beckerman, Steven R. Zeldenrust et al. · Muscle & Nerve · 2006 · 146 citations

Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist Stimulates Insulin Secretion in Rodents and From Human Islets

Kyle W. Sloop, Francis S. Willard, Martin Brenner et al. · Diabetes · 2010 · 139 citations · Full text